Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles

• Published in: Vaccine Vol. 22; no. 27; pp. 3535 - 3545
• Main Authors: Puaux, Anne-Laure, Marsac, Delphine, Prost, Stéphane, Singh, Mandal K, Earl, Patricia, Moss, Bernard, Le Grand, Roger, Riviere, Yves, Michel, Marie-Louise
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 09.09.2004; Elsevier; Elsevier Limited
• Subjects: Acquired immune deficiency syndrome; AIDS; AIDS Vaccines - therapeutic use; Animals; Antigens; Applied microbiology; Area Under Curve; Atoms & subatomic particles; Biological and medical sciences; CD4-Positive T-Lymphocytes - immunology; Cell Division - drug effects; Cytomegalovirus; Cytomegalovirus - genetics; Deoxyribonucleic acid; DNA; DNA - genetics; DNA - immunology; DNA immunisation; DNA Probes; Enzyme-Linked Immunosorbent Assay; Fundamental and applied biological sciences. Psychology; Genetic Vectors; HBsAg; Hepatitis; Hepatitis B Surface Antigens - genetics; Hepatitis B Surface Antigens - immunology; Hepatitis B virus; HIV; HIV - immunology; Human immunodeficiency virus; Human immunodeficiency virus 1; Immunization; Immunization, Secondary; Immunogenicity; Infections; Interferon-gamma; Kinetics; Lymphocytes; Macaca mulatta; Microbiology; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Rhesus macaque; SAIDS Vaccines - therapeutic use; SHIV; Simian immunodeficiency virus; Simian Immunodeficiency Virus - immunology; Simian/human immunodeficiency virus; T cell receptors; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, DNA - therapeutic use; Vaccines, Subunit - therapeutic use; Vaccinia - immunology; Viral infections; Virology; Virus Replication; HBsAg; Rhesus macaque; SHIV; DNA immunisation; Immunization; Hepatitis B surface antigen; Recombinant virus; Orthohepadnavirus; Retroviridae; Cellular immunity; Macaca mulatta; Vaccine; Lentivirus; Virus; Vertebrata; Mammalia; Hepadnaviridae; Primates; Simioidea; Hepatitis B virus; Human immunodeficiency virus; Simian immunodeficiency virus
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2004.03.044

Recent efforts to design an human immunodeficiency virus type 1 (HIV-1) vaccine candidate have focused on means of eliciting anti-viral T-cell responses. We tried to improve the immunogenicity of DNA vaccines by designing hybrid DNA constructs encoding hepatitis B surface antigen (HBsAg) fused to antigenic domains of simian/human immunodeficiency virus (SHIV 89.6P). Immunisation with hybrid DNA induced both effector and long-lasting precursor T-cells. Following boosting with a recombinant modified vaccinia Ankara (rMVA) producing full-length SIV and HIV antigens, it appeared that priming with hybrid DNA had increased virus-specific T-cell responses in terms of both the number of virus-specific IFN-γ-secreting T-cells and virus-specific lymphoproliferation. After intrarectal challenge with SHIV 89.6P, immunised animals demonstrated early control of SHIV 89.6P replication and stable CD4+ T-cell counts.